Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Nano Pharmaceutical Developed to Target Cancer Cells

Abstract:
An Iranian knowledge-based company has managed to develop a nano-pharmaceutical that targets cancerous cells and helps treat recurrent cancers.

Nano Pharmaceutical Developed to Target Cancer Cells

Tehran, Iran | Posted on October 10th, 2018

Drugs used to treat cancer are mainly divided into biological and chemical ones. In the biological treatment, which is a common cancer treatment, cancerous tissue is targeted. However, by using nanotechnology, the nano-particles take responsibility for transporting albumin into the cancerous cell.

This increases the quality, the speed of drug distribution, and the effectiveness of the medicine. This system is especially effective for the cancers that have undergone a course of treatment and are recurrent.

Nanodarou Company was founded with a small investment as a knowledge-based firm by the students and professors of Tehran University of Medical Sciences in 2011, when the Resistance Economy was introduced and recommended by the Leader of Iran’s Islamic Revolution.

The difficulty was that no imported or domestic samples of this drug were available. Despite many complications, the drug entered the market in 2016. Within three months, it was also sold in Turkey. It is now known to be the definitive medication for recurrent cancer. The production of these drugs requires a safe environment for the workers which is provided by the company.

It is currently used to treat metastatic breast cancer, pancreatic cancer, lung cancer, ovarian cancer and stomach cancer. The main purpose of producing these drugs is to increase the patient’s life and improve his/her quality of life during the course of treatment. It means that despite the illness, there is no pain in these diseases, and the patient can have normal life.

Another product of this company is the addiction treatment drug that is produced by macrospheric technique (spherical particles) and injected deep into the body of the patient and continuously released in a patient’s body within a month.

In this way, the need for the opiate disappears and the receptors of pleasure fail, and ultimately it is fully treated between 6 and 24 months.

In the past year, 8,000 doses of these drugs have been consumed; and about half of them have been sold in Turkish markets.

These medications are currently exported to five countries of the world, and nine other countries will receive them as soon as possible.

The Nanodarou Company will be present at the 2018 International Nanotechnology Exhibition, which will be held from October 13 to 16 in the Iranian capital Tehran.

####

For more information, please click here

Contacts:
Iran Front Page
Phone: 02177528888

Copyright © IFP News

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Cancer

Shape-shifting sensors could catch early signs of cancer October 19th, 2018

News and information

Shape-shifting sensors could catch early signs of cancer October 19th, 2018

Study provides insight into how nanoparticles interact with biological systems: Findings can help scientists engineer nanoparticles that are ‘benign by design’ October 18th, 2018

Iran Produces Cooling Fabrics Using Nanotechnology October 17th, 2018

Iran World’s Second Largest Producer of Nano-Catalysts October 17th, 2018

Possible Futures

Shape-shifting sensors could catch early signs of cancer October 19th, 2018

Study provides insight into how nanoparticles interact with biological systems: Findings can help scientists engineer nanoparticles that are ‘benign by design’ October 18th, 2018

Iran Unveils Its First Homegrown 3D Nano Printer October 17th, 2018

Rice U. announces $82 million in strategic research initiatives: Faculty, programs will expand in neuroengineering, synthetic biology, physical biology October 16th, 2018

Nanomedicine

Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics October 17th, 2018

Big award enables study of small surfaces: Rice U.'s Matt Jones wins Packard Fellowship to view nanoscale chemical reactions October 15th, 2018

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3 October 15th, 2018

180 Degree Capital Corp. Announces New Portfolio Holdings – Airgain, Inc., EMCORE Corporation, Lantronix, Inc. and PDL BioPharma, Inc. October 12th, 2018

Discoveries

Shape-shifting sensors could catch early signs of cancer October 19th, 2018

Study provides insight into how nanoparticles interact with biological systems: Findings can help scientists engineer nanoparticles that are ‘benign by design’ October 18th, 2018

Researchers quickly harvest 2-D materials, bringing them closer to commercialization: Efficient method for making single-atom-thick, wafer-scale materials opens up opportunities in flexible electronics October 12th, 2018

Graphene shows unique potential to exceed bandwidth demands of future telecommunications October 12th, 2018

Announcements

Shape-shifting sensors could catch early signs of cancer October 19th, 2018

Study provides insight into how nanoparticles interact with biological systems: Findings can help scientists engineer nanoparticles that are ‘benign by design’ October 18th, 2018

Iran Unveils Its First Homegrown 3D Nano Printer October 17th, 2018

Fat-Repellent Nanolayers Can Make Oven Cleaning Easier October 17th, 2018

Events/Classes

Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics October 17th, 2018

Iran Produces Cooling Fabrics Using Nanotechnology October 17th, 2018

Iran World’s Second Largest Producer of Nano-Catalysts October 17th, 2018

Iran Unveils Its First Homegrown 3D Nano Printer October 17th, 2018

Nanobiotechnology

Arrowhead Pharmaceuticals Hosts R&D Day on Pipeline of RNAi Therapeutics October 17th, 2018

Big award enables study of small surfaces: Rice U.'s Matt Jones wins Packard Fellowship to view nanoscale chemical reactions October 15th, 2018

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3 October 15th, 2018

180 Degree Capital Corp. Announces New Portfolio Holdings – Airgain, Inc., EMCORE Corporation, Lantronix, Inc. and PDL BioPharma, Inc. October 12th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project